#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should understand that CBD is increasingly recommended by nutrition professionals as a sleep aid, despite limited clinical evidence for its efficacy and safety in sleep disorders. Patients asking about CBD for insomnia need evidence-based counseling on the lack of FDA approval, variable product quality, and potential drug interactions, particularly with medications metabolized by CYP3A4. Healthcare providers should stay informed about patient use of CBD supplements given their widespread availability and popularity, which may affect medication management and treatment planning.
This article reviews sleep supplements recommended by dietitians, including cannabidiol (CBD), which modulates the endocannabinoid system to influence stress, mood, and sleep regulation. While CBD is increasingly used by patients seeking non-pharmaceutical sleep interventions, the evidence base for its efficacy in insomnia remains limited and inconsistent, with most studies involving small sample sizes and lack of standardization in dosing or formulation. Clinicians should be aware that patients may self-select CBD products without medical guidance, and the unregulated supplement market means considerable variability in product quality, purity, and actual CBD content compared to labeled amounts. Understanding the proposed mechanisms of action and current evidence gaps is important for clinicians counseling patients about sleep management options and potential drug interactions with sedating medications or other supplements. Practitioners should ask patients directly about CBD and other supplement use for sleep and provide evidence-based guidance on proven behavioral interventions while acknowledging the preliminary nature of CBD research in this indication.
“We’re seeing some encouraging preliminary signals that CBD may influence sleep through endocannabinoid pathways, but I want to be clear with patients that the human clinical evidence here is still quite limited, and we need more rigorous, placebo-controlled trials before I can recommend it with the same confidence I would other sleep interventions.”
🛌 While CBD is increasingly marketed as a sleep aid and some patients report subjective improvement in sleep quality, the clinical evidence supporting its efficacy remains limited and heterogeneous, with most studies involving small sample sizes and varied dosing protocols. The mechanism by which CBD might improve sleep—whether through anxiolytic effects, direct effects on sleep architecture, or placebo response—remains incompletely understood, and products marketed as sleep supplements often lack standardized dosing or third-party quality verification. Clinicians should be aware that CBD can interact with hepatically metabolized medications and may cause sedation, dizziness, or gastrointestinal effects, particularly at higher doses or in vulnerable populations. Rather than endorsing CBD as a first-line recommendation, providers should explore conventional sleep hygiene measures, cognitive behavioral therapy for insomnia, and evidence-based pharmacotherapy first, while remaining open to discussing CBD if patients inquire, armed with honest acknowledgment
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
